Price
No data yet.
Social Signal Score
Analyst Ratings
11 analystsRevenue
$91.86M+222.56%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Sheri Louise Dodd
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 1,086
- Beta
- 0.89
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 7.99
Financials
Revenue
$91.86M+222.6%Net Income
$7.16M+201.0%EBITDA
$11.43M+234.5%Free Cash Flow
$11.43M+374.9%EPS (diluted)
$0.31+121.4%Shares Outstanding (diluted)
23.05M+36.9%Operating Expenses
$60.20MCash & Debt
$75.11MReturn of Capital
$6.17MRevenue by Segment (annual)
$329.52MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $329.52M | $19.09M | $0.83 |
| 2024 | $292.98M | $16.96M | $0.71 |
| 2023 | $274.42M | $28.52M | $1.24 |
| 2022 | $246.78M | $-17.87M | $-0.89 |
| 2021 | $208.06M | $-11.81M | $-0.60 |
| 2020 | $187.13M | $-620.0K | $-0.03 |
| 2019 | $189.49M | $10.97M | $0.58 |
| 2018 | $143.75M | $6.62M | $0.34 |
| 2017 | $109.28M | $5.86M | $0.34 |
| 2016 | $84.54M | $2.88M | $0.18 |
| 2015 | $62.87M | $1.39M | $-0.03 |
| 2014 | $47.74M | $2.07M | $0.01 |
| 2013 | $37.18M | $3.16M | $1.33 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from TCMD's reported EPS growth of -3.9% a year over 12 years.
- EPS in 5 years
- $0.68
- Implied price
- $23.94
- Return from $25.99
- -1.6% a year
To earn 15.0% a year on these assumptions you'd need to buy at $11.90 — -54.2% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 25 | 30 | 35 | 40 | 45 |
|---|---|---|---|---|---|
| -13.9% | -17.6% | -14.5% | -11.9% | -9.5% | -7.3% |
| -8.9% | -12.8% | -9.6% | -6.7% | -4.2% | -1.9% |
| -3.9% | -8.0% | -4.6% | -1.6% | 1.0% | 3.4% |
| 1.1% | -3.2% | 0.3% | 3.5% | 6.3% | 8.8% |
| 6.1% | 1.5% | 5.3% | 8.6% | 11.5% | 14.2% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
70+40.00%Social Signal Score
Mentions (13)
- Newszacks.com·2d ago·Positive
Wall Street Analysts See a 39.78% Upside in Tactile Systems Technology (TCMD): Can the Stock Really Move This High? The mean of analysts' price targets for Tactile Systems Technology (TCMD) points to a 39.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
View source ↗ - Newsglobenewswire.com·4d ago·Neutral
…Sandler 38th Annual Healthcare Conference MINNEAPOLIS, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that management will participate in a fireside chat at the Piper Sandler 38th Annual Healthcare Conference, which is being held at the Lotte New York Palace in New York, NY, from December 1-3, 2026. The fireside chat will take …
View source ↗ - Newszacks.com·18d ago·Neutral
Wall Street Analysts Think Tactile Systems Technology (TCMD) Could Surge 52.02%: Read This Before Placing a Bet The average of price targets set by Wall Street analysts indicates a potential upside of 52% in Tactile Systems Technology (TCMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
View source ↗ - Newszacks.com·18d ago·Positive
Tactile Systems Technology (TCMD) Just Overtook the 20-Day Moving Average After reaching an important support level, Tactile Systems Technology (TCMD) could be a good stock pick from a technical perspective. TCMD surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.
View source ↗ - Newsfool.com·19d ago·Neutral
Tactile Systems: 3 Key Takeaways for Long-Term Investors Lymphedema product revenue increased 13% year over year to $81.8 million. Technology improvements reduced medical record review times by approximately 50%.
View source ↗ - Newsseekingalpha.com·20d ago·Positive
Tactile Systems Technology, Inc. (TCMD) Q3 2026 Earnings Call Transcript Tactile Systems Technology, Inc. (TCMD) Q3 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·20d ago·Neutral
What Tactile Systems Technology (TCMD) Said on Its Q3 Earnings Call Tactile Systems Technology NASDAQ: TCMD, which operates as Tactile Medical, reported third-quarter revenue of $91.9 million, up 7.1% from a year earlier, as continued double-digit growth in its lymphedema business offset an expected decline in airway-clearance sales tied to distributor inventory transitions.
View source ↗ - Newszacks.com·20d ago·Positive
Tactile Systems Technology (TCMD) Q3 Earnings Surpass Estimates Tactile Systems Technology (TCMD) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.3 per share. This compares to earnings of $0.36 per share a year ago.
View source ↗ - Newsfool.com·20d ago·Neutral
Tactile Medical's Spending Outpaces Sales: Rapid Earnings Reaction Lymphedema sales grew at a double-digit pace again, while the smaller airway clearance line shrank. Higher sales and administrative spending pushed operating income below last year's level.
View source ↗ - Newsglobenewswire.com·20d ago·Neutral
Tactile Systems Technology, Inc. Reports Third Quarter 2026 Financial Results MINNEAPOLIS, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the third quarter ended September 30, 2026.
View source ↗ - Newsglobenewswire.com·34d ago·Neutral
Tactile Medical to Release Third Quarter of Fiscal Year 2026 Financial Results on November 2, 2026 MINNEAPOLIS, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that third quarter of fiscal year 2026 financial results will be released after the market closes on Monday, November 2, 2026.
View source ↗ - Newsseekingalpha.com·104d ago·Positive
Tactile Systems Technology, Inc. (TCMD) Q2 2026 Earnings Call Transcript Tactile Systems Technology, Inc. (TCMD) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·104d ago·Neutral
Tactile Systems Technology Q2 Earnings Call Highlights Tactile Systems Technology NASDAQ: TCMD, doing business as Tactile Medical, reported second-quarter revenue growth and higher profitability, led by its lymphedema business, while updating its full-year outlook to reflect temporary inventory effects in its airway-clearance segment.
View source ↗
Earnings
Tue, Feb 16(in 3 months)
Consensus estimate $0.53 per share
Typical surprise +12.0% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 2$0.31 vs $0.28beat
- Mon, Aug 10$0.34 vs $0.14beat
- Mon, May 4$-0.08 vs $-0.07miss
- Tue, Feb 17$0.46 vs $0.44beat
- Mon, Nov 3$0.36 vs $0.16beat
- Mon, Aug 4$0.14 vs $0.09beat
Estimates and results for TCMD via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TCMD officers and directors.
- Bought
- —
- Sold
- $3.8m
0 trades
37 trades
- Burke William Wsold
- King Laura G.sold
- Dodd Sheri Louisesold
- Birkemeyer Elaine M.sold
- Dodd Sheri Louisesold
- Birkemeyer Elaine M.sold
- Burns Kristiesold
- Birkemeyer Elaine M.sold
63 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Tina Smithsenate · MN · disclosed Nov 21, 2024 (9d later)Buy$50,001 - $100,000
- Tina Smithsenate · MN · disclosed Nov 20, 2023 (12d later)Buy$100,001 - $250,000
- Donna Shalalahouse · FL27 · disclosed Apr 27, 2020 (460d later)Buy$1,001 - $15,000
- Tina Smithsenate · MN · disclosed Jun 11, 2018 (10d later)Sell$100,001 - $250,000
- Tina Smithsenate · MN · disclosed Jun 11, 2018 (10d later)Sell$100,001 - $250,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
